Key Laboratory of Medical Electrophysiology, Ministry of Education, School of Pharmacy, Southwest Medical University, No.319, Sanduan of Zhongshan Rd., Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China.
The Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, No.16, Chunhui Road, Longma Tan District, Luzhou, 646000, Sichuan Province, People's Republic of China.
AAPS PharmSciTech. 2020 Jun 11;21(5):170. doi: 10.1208/s12249-020-01711-2.
Felodipine (FLD), a dihydropyridine calcium channel blocker with excellent antihypertensive effect, is poorly soluble and undergoes extensive hepatic metabolism, which lead to poor oral bioavailability (about 15%) and limit its clinic application. The goal of this study was to develop solid lipid nanoparticles (SLNs) loading FLD to improve the oral bioavailability. The FLD loaded solid lipid nanoparticles (FLD-SLNs) were prepared by the effervescent dispersion technique developed by our laboratory, which might have some advantages over traditional methods. The FLD-SLNs showed desired particle characteristics with particle size (198.15 ± 1.82 nm), poly dispersity index (0.26 ± 0.02), zeta-potential (- 25.53 ± 0.60 mV), entrapment efficiency (95.65 ± 0.70%), drug loading (2.33 ± 0.10%), and a spherical appearance. Pharmacokinetic results showed that the FLD-SLNs presented 3.17-fold increase in area under the curve (AUC) compared with free FLD after oral administration in beagle dogs, which indicated that SLNs prepared using the effervescent dispersion technique can improve the bioavailability of lipophilic drugs like felodipine by enhancement of absorption and reduction first-pass metabolism.
非洛地平(FLD)是一种二氢吡啶钙通道阻滞剂,具有优异的降压效果,但溶解度差,广泛进行肝代谢,导致口服生物利用度差(约 15%),限制了其临床应用。本研究旨在开发载有 FLD 的固体脂质纳米粒(SLNs),以提高口服生物利用度。采用我们实验室开发的泡腾分散技术制备载有 FLD 的固体脂质纳米粒(FLD-SLNs),可能优于传统方法。FLD-SLNs 具有理想的颗粒特性,粒径(198.15±1.82nm)、多分散指数(0.26±0.02)、Zeta 电位(-25.53±0.60mV)、包封效率(95.65±0.70%)、载药量(2.33±0.10%)和球形外观。药代动力学结果表明,与口服游离 FLD 相比,犬口服 FLD-SLNs 后曲线下面积(AUC)增加了 3.17 倍,表明采用泡腾分散技术制备的 SLNs 可以通过增强吸收和减少首过代谢来提高亲脂性药物如非洛地平的生物利用度。